Navigation Links
Therapure Biopharma Inc. Announces Delivery of its First Commercial-Scale Lyophilizer
Date:11/8/2009

Freeze-drying of biopharmaceuticals to be available at the Company’s Mississauga, Ontario facility.

Toronto, ON (PRWEB) November 8, 2009 -- Thomas Wellner, President and CEO of Therapure Biopharma Inc. today announced that the Company has taken delivery of a commercial scale pharmaceutical grade freeze dryer and expects to make commercial scale freeze drying (lyophilization) available for contract manufacturing of biopharmaceuticals early in 2010.

Lyophilization is used to convert biopharmaceuticals that are manufactured in an unstable liquid format into a stable, dry powder that can be reconstituted to a liquid format for administration to patients. Lyophilized forms of these life-saving products are more easily handled and stable than their liquid forms and therefore lyophilization is commonly used in the manufacture of these products.

“Commercial scale lyophilization is not readily available in Canada,” said Thomas Wellner. “The addition of a commercial-scale lyophilizer to the clinical scale capability Therapure Biopharma has now will significantly enhance the value we will bring to Therapure clients.”

Installation of the lyophilizer began last week and is expected to be completed in December. Following the installation, the Company will complete the extensive validation process required to achieve current Good Manufacturing Practices (cGMP) status. Therapure Biopharma will begin offering commercial-scale lyophilization services from its Health Canada commercially licensed plant early in 2010.

About Therapure Biopharma:
Therapure Biopharma Inc. is an integrated biopharmaceutical company that develops, manufactures, purifies, and packages therapeutic proteins. As a contract development and manufacturing organization (CDMO) Therapure Biopharma applies scientific, manufacturing, and downstream purification expertise with an intimate understanding of advanced biology, complex proteins, and regulatory processes to develop effective and innovative solutions to advance products from discovery to market.

For more information, please visit: www.therapurebio.com

Media Contacts:
Thomas Wellner, President and CEO
Therapure Biopharma Inc.
+1 905-286-6204

# # #

Read the full story at http://www.prweb.com/releases/2009/11/prweb3172054.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related medicine news :

1. Therapure Biopharma Inc. and LFB Biotechnologies Announce Development Services Contract for New Therapeutic Protein
2. Surviving Healthcare Reform: How Biopharma Companies Can Come Out on Top
3. aTyr Pharma to Present at Japan Biopharma Partnering Conference
4. Keryx Biopharmaceuticals, Inc. to Hold Investor/Analyst Day Tomorrow
5. DOR BioPharma Announces $9.4 Million NIH Grant Award to Develop Thermostable and Rapidly Acting Vaccines
6. PDL BioPharma Announces Conversion Rate Adjustment for Its 2.75% Convertible Subordinated Notes Due August 16, 2023
7. Keryx Biopharmaceuticals Receives Orphan-Drug Designation for KRX-0401 (Perifosine) for the Treatment of Multiple Myeloma
8. UK's Newcastle University Introduces First-Ever Biopharmaceutical Engineering Doctorate Program
9. PDL BioPharma to Present at BioCentury Newsmakers Conference on September 16, 2009
10. Frost & Sullivan Global Heart Health Ingredients Excellence in Financial & Risk Management Award Conferred on Pronova BioPharma
11. Keryx Biopharmaceuticals, Inc. To Present at the Rodman & Renshaw Annual Global Investment Conference and To Hold Investor/Analyst Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... Aliso Viejo, California (PRWEB) , ... June 25, 2016 , ... ... preset to fit their specific project," said Christina Austin - CEO of Pixel Film ... all fully customizable and all within Final Cut Pro X . Simply select ...
(Date:6/25/2016)... ... 2016 , ... Conventional wisdom preaches the benefits of moderation, whether it’s a ... the bar too high can result in disappointment, perhaps even self-loathing. However, those who ... , Research from PsychTests.com reveals that behind the tendency to set ...
(Date:6/24/2016)... ... June 24, 2016 , ... The ... in Dallas that it will receive two significant new grants to support its ... PHA marked its 25th anniversary by recognizing patients, medical professionals and scientists for ...
(Date:6/24/2016)... ... 2016 , ... People across the U.S. are sharpening their pencils and honing ... contest in which patients and their families pay tribute to a genetic counselor by ... Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , In ...
(Date:6/24/2016)... ... 24, 2016 , ... National recruitment firm Slone Partners is pleased ... and genomics experience, as Vice President of North American Capital Sales at HTG ... leading the sales team in the commercialization of the HTG EdgeSeq system and associated ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on ... today announced that patient enrollment in its ongoing ... Duchenne) has exceeded 50% of its 24-patient target. ... in the third quarter of 2016, and to ...
(Date:6/23/2016)... and BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of Astellas ... Brasil as the company,s second affiliate in Latin America . ... ... of Astellas Farma Colombia ... ...
(Date:6/23/2016)... , June 23, 2016  Experian ... integrating and transforming the patient payment and ... several innovative new products and services that ... its revenue cycle offerings. These award-winning solutions ... efficient workflows, remain compliant in an ever-changing ...
Breaking Medicine Technology: